Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE.

He lives financially free trading this One Stock Once per month...
Ticker Revealed.

Thomas Tray Biography and Net Worth

Insider of Incyte


Thomas Tray is the VP of Fin., Chief Accounting Officer & Controller at Incyte.

What is Thomas Tray's net worth?

The estimated net worth of Thomas Tray is at least $1.18 million as of July 22nd, 2022. Mr. Tray owns 17,702 shares of Incyte stock worth more than $1,179,130 as of September 29th. This net worth approximation does not reflect any other assets that Mr. Tray may own. Learn More about Thomas Tray's net worth.

How old is Thomas Tray?

Mr. Tray is currently 44 years old. There are 8 older executives and no younger executives at Incyte. The oldest executive at Incyte is Ms. Pamela M. Murphy, VP of Investor Relations & Corp. Communications, who is 71 years old. Learn More on Thomas Tray's age.

How do I contact Thomas Tray?

The corporate mailing address for Mr. Tray and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected] Learn More on Thomas Tray's contact information.

Has Thomas Tray been buying or selling shares of Incyte?

Within the last three months, Thomas Tray has sold $130,015.32 in Incyte stock. Most recently, Thomas Tray sold 1,564 shares of the business's stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $83.13, for a transaction totalling $130,015.32. Following the completion of the sale, the insider now directly owns 17,702 shares of the company's stock, valued at $1,471,567.26. Learn More on Thomas Tray's trading history.

Who are Incyte's active insiders?

Incyte's insider roster includes Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Herve Hoppenot (President), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.

Are insiders buying or selling shares of Incyte?

During the last twelve months, Incyte insiders bought shares 6 times. They purchased a total of 2,137,539 shares worth more than $153,065,544.39. During the last twelve months, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 89,978 shares worth more than $6,074,106.53. The most recent insider tranaction occured on July, 22nd when insider Thomas Tray sold 1,564 shares worth more than $130,015.32. Insiders at Incyte own 17.5 % of the company. Learn More about insider trades at Incyte.

Information on this page was last updated on 7/22/2022.

Thomas Tray Insider Trading History at Incyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/22/2022Sell1,564$83.13$130,015.3217,702View SEC Filing Icon  
See Full Table

Thomas Tray Buying and Selling Activity at Incyte

This chart shows Thomas Tray's buying and selling at Incyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Incyte Company Overview

Incyte logo
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $66.61
Low: $66.14
High: $67.58

50 Day Range

MA: $72.48
Low: $66.18
High: $82.86

2 Week Range

Now: $66.61
Low: $61.91
High: $84.86

Volume

1,263,072 shs

Average Volume

1,525,384 shs

Market Capitalization

$14.82 billion

P/E Ratio

15.67

Dividend Yield

N/A

Beta

0.66